Literature DB >> 20472112

Induction of fetal demise before abortion.

Justin Diedrich, Eleanor Drey.   

Abstract

For decades, the induction of fetal demise has been used before both surgical and medical second-trimester abortion. Intracardiac potassium chloride and intrafetal or intra-amniotic digoxin injections are the pharmacologic agents used most often to induce fetal demise. In the last several years, induction of fetal demise has become more common before second-trimester abortion. The only randomized, placebo-controlled trial of induced fetal demise before surgical abortion used a 1 mg injection of intra-amniotic digoxin before surgical abortion at 20-23 weeks' gestation and found no difference in procedure duration, difficulty, estimated blood loss, pain scores or complications between groups. Inducing demise before induction terminations at near viable gestational ages to avoid signs of life at delivery is practiced widely. The role of inducing demise before dilation and evacuation (D&E) remains unclear, except for legal considerations in the United States when an intact delivery is intended. There is a discrepancy between the one published randomized trial that used 1 mg intra-amniotic digoxin that showed no improvement in D&E outcomes and observational studies using different routes, doses and pre-abortion intervals that have made claims for its use. Additional randomized trials might provide clearer evidence upon which to make further recommendations about any role of inducing demise before surgical abortion. At the current time, the Society of Family Planning recommends that pharmacokinetic studies followed by randomized controlled trials be conducted to assess the safety and efficacy of feticidal agents to improve abortion safety.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20472112     DOI: 10.1016/j.contraception.2010.01.018

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  7 in total

1.  Induction of fetal demise before pregnancy termination: practices of family planning providers.

Authors:  Colleen C Denny; Michele B Baron; Lauren Lederle; Eleanor A Drey; Jennifer L Kerns
Journal:  Contraception       Date:  2015-05-18       Impact factor: 3.375

2.  A new and more effective feticide technique in late termination of pregnancy: potassium chloride injection into the interventricular septum of the fetal heart.

Authors:  Sema Süzen Çaypınar; Süleyman Cemil Oğlak; İbrahim Polat; Kübra Kurt Bilirer; Salim Sezer; Zeynep Gedik Özköse; Sema Karakaş
Journal:  Arch Gynecol Obstet       Date:  2022-10-21       Impact factor: 2.493

3.  Foetal radiography for suspected skeletal dysplasia: technique, normal appearances, diagnostic approach.

Authors:  Alistair D Calder; Amaka C Offiah
Journal:  Pediatr Radiol       Date:  2014-08-31

4.  Diagnostic assessment of foetal brain malformations with intra-uterine MRI versus perinatal post-mortem MRI.

Authors:  Stacy K Goergen; Ekaterina Alibrahim; Nishentha Govender; Alexandra Stanislavsky; Christian Abel; Stacey Prystupa; Jacquelene Collett; Susan C Shelmerdine; Owen J Arthurs
Journal:  Neuroradiology       Date:  2019-05-10       Impact factor: 2.804

5.  Drugs used to induce fetal demise prior to abortion: a systematic review.

Authors:  Tesfaye H Tufa; Sarah Prager; Antonella F Lavelanet; Caron Kim
Journal:  Contracept X       Date:  2020-11-09

6.  Effectiveness of intra-cardiac lidocaine and intra-amniotic digoxin at inducing fetal demise before second trimester abortion past 20 weeks at a tertiary Hospital in Ethiopia: A retrospective review.

Authors:  Abraham Fessehaye Sium; Tesfaye H Tufa; Jaclyn M Grentzer; Sarah Prager
Journal:  Contracept X       Date:  2022-07-31

7.  Feasibility of intra-amniotic digoxin administration by obstetrics and gynecology trainees to induce fetal demise prior to medical abortion beyond 20 weeks.

Authors:  Tesfaye Hurissa Tufa; Antonella Francheska Lavelanet; Lemi Belay; Berhanu Seboka; Jason Bell
Journal:  BMJ Sex Reprod Health       Date:  2020-04-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.